海曲泊帕乙醇胺片 | China Drugs ListHetrombopag olamine tablets | China Drugs List

本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

药品类型: 化学药Chemical medicine
治疗领域: 非恶性血液疾病Non-malignant blood disorders
公开来源记录的适应症: ①既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症（ITP）成人及≥6岁儿童，使血小板计数升高并减少或防止出血；仅用于因血小板减少及临床条件导致出血风险增加的患者。②对免疫抑制治疗（IST）疗效不佳的重型再生障碍性贫血（SAA）成人患者。③联合免疫抑制治疗，用于≥15岁初治SAA患者。④用于实体瘤化疗为主的抗肿瘤治疗所致血小板减少症（CTIT）成人患者。1. Adults and children aged 6 years or older with chronic primary immune thrombocytopenia (ITP) who responded inadequately to corticosteroids, immunoglobulins or other therapies, to increase platelet counts and reduce or prevent bleeding. Use is restricted to patients whose thrombocytopenia and clinical condition increase their risk of bleeding. 2. Adults with severe aplastic anemia (SAA) who responded inadequately to immunosuppressive therapy (IST). 3. In combination with IST for previously untreated SAA in patients aged 15 years or older. 4. Adults with thrombocytopenia caused by anticancer treatment based primarily on chemotherapy for solid tumors (CTIT).
适应症来源与口径: 来源日期： 2026-08-04, 2026-09. 包括由获批公告支持的适应症；适用说明书版本请见链接来源。新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2026-08-04, 2026-09. Includes indications supported by approval announcements; see the linked sources for the applicable label version. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
说明书信息局限: 已取得完整官方药品说明书。中国大陆说明书。 2026年新增适应症由生产商获批公告支持。生产商原始页面图像已按顺序保存。Complete official prescribing information obtained. Mainland China label. Additional 2026 indications are supported by manufacturer approval announcements. Original manufacturer page images have been preserved in order.
中国可获得性状态: 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
海外状态: 待逐一核查各市场。Market-by-market verification pending.
医保分类: 已纳入国家医保（乙类）Included in national insurance (Category B)
医保版本: 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
医保限制: 限：1.既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者；2.对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。Limited to: 1. Adults with chronic primary ITP who responded inadequately to corticosteroids, immunoglobulins or other therapies. 2. Adults with SAA who responded inadequately to IST.
医保期限: 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
医保核查说明: 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

来源

打开交互详情、公开价格与讨论